Efficacy of immune checkpoint inhibitors in different types of melanoma
Immunotherapy can be used for cutaneous, mucosal, uveal and conjunctival melanoma. Nevertheless, we cannot expect the same benefit from checkpoint inhibitors for all the types of melanoma. The different biological features can explain the variable efficacy. The main results obtained with immune chec...
Main Authors: | Ernesto Rossi, Giovanni Schinzari, Brigida Anna Maiorano, Giulia Indellicati, Alessandro Di Stefani, Monica Maria Pagliara, Simona Maria Fragomeni, Erika Valentina De Luca, Maria Grazia Sammarco, Giorgia Garganese, Jacopo Galli, Maria Antonietta Blasi, Gaetano Paludetti, Giovanni Scambia, Ketty Peris, Giampaolo Tortora |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2020.1771986 |
Similar Items
-
The Clinical Feature and Treatment Outcome of Ocular Melanoma: A 34-Year Experience in a Tertiary Referral Center
by: Yu-Yun Huang, et al.
Published: (2021-11-01) -
So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020
by: Manuel Rodrigues, et al.
Published: (2019-07-01) -
Genetics of Ocular Melanoma: Insights into Genetics, Inheritance and Testing
by: Natasha M. van Poppelen, et al.
Published: (2020-12-01) -
Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study
by: Ernesto Rossi, et al.
Published: (2022-05-01) -
Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know
by: Kalijn Fredrike Bol, et al.
Published: (2020-07-01)